A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key ...

A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key ...

HOUSTON, MAY 20, 2026 ― A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key ...

The University of Texas MD Anderson Cancer Center in Houston launched a clinical collaboration with Pfizer to study the use of immuno-oncology drugs to treat various solid tumors and blood cancers.

Major themes include strategies to reprogram the tumor microenvironment and prevent cancer before it starts New insights from AI-based imaging, B-cell biology and mRNA vaccine technology point to more ...

Cancer-induced nerve injury, a cause of chronic inflammation, may lead to immunotherapy resistance, according to a study published Aug. 20 in Nature. The research was led by teams from Houston-based ...

Some patients treated with immunotherapy may develop lifelong endocrine conditions requiring ongoing hormone replacement, ...

With classic chemotherapy drugs, you know that you're going to give the chemotherapy and a day or two later, you're going to have side effects. With immunotherapy, the side effects can happen at any ...

A major national effort to expand the reach of cancer immunotherapy to benefit more patients will draw upon the expertise of a team of researchers at The University of Texas MD Anderson Cancer Center.

SAN DIEGO – A new AI model applied to routine pathology slides accurately predicts outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC). The study was ...

After nearly 100 years of development, treatments that bolster the body's immune system to fight cancer are coming of age – and saving patients' lives.